DOCSLIB.ORG

University of Toronto Medical Journal University of Toronto a Student-Run Scientific Publication

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Toronto Medical Journal University of Toronto a Student-Run Scientific Publication UTMJ UTMJ University of Toronto Medical Journal DECEMBER 2000 Volume 78, Number 1/December, 2000 A student-run scientific publication. Established in 1923. 4 Letter to Patrons 26 Clinicopathological Correlation 5 Preface 38 News and Views 8 Patients with Facial Difference: Assessment of 58 Morning Report Information and Psychosocial Support Needs Karen M. Horton, Lorna Renooy and Christopher R. Forrest 63 Quick Diagnosis 14 Dystrophinopathies and Nondystrophinopathies: 68 Technology Review From Molecular Biology to Clinical Diagnosis Lorraine V. Hajdur and Suneil K. Kalia 71 Historical Review VOLUME 78 / No 1 22 Phantom Menace: The Mystery of Phantom Limb Pain: 73 Book Reviews A Case Report and Review of the Literature Sonja Alexandra McVeigh 81 Crossword www.utmj.org An excellent routetoreach Healthcare your patients’lipid targets Pharmaceuticals Life-Saving Plasma Products Choose Equipment and Products first! to Diagnose Human Health In achieving effective lipid control, many delays may prevent you from reaching your targets. LIPITOR lane Possible delays ahead clear ahead NewNew clinicalclinical datadata New data1 showed LIPITOR actually gets patients to tar- get§ with fewer titrations and fewer repeat visits than Zocor ®, Mevacor ®, or Lescol®. Give your new statin patients the benefits of LIPI- Exceptional LDL-C reductions – 39-60% over the full dose range2 Significantly better LDL-C and TC/HDL-C ratio reductions, compared to Zocor or Pravachol® at starting doses3,4,5∞‡ The added benefit of excellent TG reductions – 19-37% over the full dose range2 Priced to be competitive – LIPITOR costs less than Zocor or Pravachol at usual starting doses6 An excellent first choice when you choose statintherapy. § Randomized, 54-week, 30 centre controlled trial treating 662 patients to NCEP targets using atorvastatin, simvastatin, lovastatin, and fluvastatin. Pravastatin was There are many ways to say Bayer not included in the study since its lipid-lowering profile is between that of fluvastatin and simvastatin, and at the time of study initiation, it was not as widely prescribed as lovastatin. ∞ Results at 16 weeks in a study of 177 hypercholesterolemic patients taking LIPITOR 10 mg or Zocor 10 mg in a one-year, randomized, double-blind study. The LIPITOR group had LDL-C and TC reductions of 37% and 29% and an HDL-C increase of 7%, while the Zocor group had LDL-C and TC reductions of 30% and 24% respectively (p<0.05) and an HDL-C increase of 7%. ‡ Results at 16 weeks in a study of 305 hypercholesterolemic patients taking LIPITOR 10 mg or Pravachol 20 mg in a one-year, randomized, double-blind study. The LIPITOR group had LDL-C and TC reductions of 35% and 25% and an HDL-C increase of 6%, while the Pravachol group had LDL-C and TC reductions of 23% and 17% respectively (p<0.05) and an HDL-C increase of 8%. LIPITOR* is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to diet for the reduction of elevated total cholesterol, LDL-C, triglycerides, and apolipoprotein B in hyperlipidemic and dyslipidemic conditions (including primary hypercholesterolemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemia, and familial hypercholesterolemia) when response to diet and other non-pharmacological measures alone has been inadequate. See prescribing information for complete warnings, precautions, dosing and administration. LIPITOR is contraindicated during pregnancy and lactation. Lipid levels should be monitored periodically and, if necessary, the dose of LIPITOR adjusted based on target lipid levels recommended by guidelines. Caution should be exercised in severely hypercholesterolemic patients who are also renally impaired, elderly, or are concomitantly being administered digoxin or CYP 3A4 inhibitors. Liver function tests should be performed before the initiation of treatment, and periodically thereafter. Special attention should be paid to patients who develop Changing the world elevated serum transaminase levels, and in these patients measurements should be repeated promptly and then performed more frequently. The effects of atorvastatin induced changes in lipoprotein levels, including reduction in serum cholesterol, on cardiovascular morbidity, mortality, or total mortality have not been established. Registered trademarks: Zocor®/Mevacor® – Merck Frosst; Pravachol® – Bristol-Myers Squibb; Lescol® – Novartis. with great care. University of TorontoUTMJ Medical Journal Volume 78, Number 1/December, 2000 A student-run scientific publication. Established in 1923. Table of Contents 4 Letter to Patrons Morning Report 58 The Young Golfer’s Swollen Leg 5 Preface Martin C. Chang and Catherine Chung Plastic Surgery Quick Diagnosis 8 Patients with Facial Difference: Assessment of 63 Piero Tartaro and Steven Hwang Information and Psychosocial Support Needs Karen M. Horton, Lorna Renooy and Christopher R. Forrest Technology Review 68 UltraLIGHT: New Frontiers in Medical Imaging Molecular Biology Victor Yang, Alex Vitkin, Maggie Gordon, Alvin Mok, 14 Dystrophinopathies and Nondystrophinopathies: Louis Wongkeesong, Paul Muller, Norman Marcon, From Molecular Biology to Clinical Diagnosis Sheldon Mintz and Brian Wilson Lorraine V. Hajdur and Suneil K. Kalia Historical Review Neurology 71 The University of Toronto as a World Leader in 22 Phantom Menace: The Mystery of Phantom Limb Medical Genetics: Past, Present and Future Pain: A Case Report and Review of the Literature Charis Kepron, Chris Lane, David Maslove, Sonja Alexandra McVeigh Vladislav Miropolsky, and Peter Zakrzewski Clinicopathological Correlation Book Reviews 26 The Parasite that Wasn’t: A Case of Detached Ciliary 73 Medical Education below the 49th Parallel Tufts in Cerebrospinal Fluid Chris McIntosh Andrea K. Boggild, Yael Friedman and Christine A. Sundermann 74 Modernizing a Class Curriculum Elana Lavine 30 A Perplexing Peripheral Neuropathy Andrew S.-P. Lim and Warren Shih 75 The Monster Psychiatrist on the Loose in Toronto Christopher Tam News and Views 38 In the Literature 76 An Updated Respiratory Classic Philippe L. Bedard Amy S.M. Tam 40 Prolific Scientist Profiles: The 2000 Gairdner Awards 76 The Vanishing Art of Prognosis Rohit Bose Lilia Malkin 42 Prolific Scientist Profiles: 78 Is There More to Life than Medicine? An Interview with Dr. Jack Hirsh, 2000 Gairdner Jacqueline H. Perry Award Winner Rohit Bose 79 Healthy Diet for Dummies Wilson W. Marhin 44 Back to Basics IV: Fracture Management Murray Beuerlein, Chris Hall and Emil H. Schemitsch 80 Being Open to Second Opinions Sanjeev Luthra 51 Law and Ethics in Medicine: The Ethics of Organ Donation: Examining Consent Policies and Donor Criteria 81 Crossword Denise Mackey and Maria Kjerulf 55 Forum: Evaluating Financial Supports for Medical Students Steve Singh Front cover illustration by Andrée Jenks and Victoria Rowsell, Department of Biomedical Communications, University of Toronto. volume 78, number 1, December 2000 1 University of TorontoUTMJ Medical Journal Room 2141, Medical Sciences Building, 1 King’s College Circle, Toronto, Ontario M5S 1A8 A student-run scientific publication. Established in 1923. UTMJ Staff EDITORS-IN-CHIEF CPC EDITORS UTMJ CROSSWORD EDITORS Prateek K. Lala, M.Sc. (0T3) Andrea K. Boggild, M.Sc. (0T3) Angela Marrocco, B.Sc., B.P.H.E. (0T3) Valerie Panet-Raymond, M.Sc. (0T3) Yael Friedman, M.Sc. (0T3) Sarah A. Shaikh, B.Sc. (0T3) Andrew S.-P. Lim, B.Sc. (0T3) SENIOR ASSOCIATE EDITORS Warren Shih, B.Sc. (0T3) EDITORIAL BOARD Michael A. Levesque, Ph.D. (0T3) Kathy Barnard, B.Sc. (0T2) Kenji S. Miyata, Ph.D. (0T3) QUICK DIAGNOSIS EDITORS Steven W.H. Hwang, B.Sc. (0T3) Sam Bederman, M.Sc. (0T1) JUNIOR ASSOCIATE EDITORS Shoba Subramanian, B.Sc. (0T3) Jonathan Dostrovsky, Ph.D. Stanley Liu, Ph.D. (0T4) Piero Tartaro, B.Sc. (0T3) Patrick Gullane, M.D., F.R.C.S.(C), F.A.C.S. Andrea Molckovsky, M.Sc. (0T4) Mohammed T. Hussain, B.Sc. (0T2) Jamie I. Spiegelman, B.Sc. (0T4) MORNING REPORT EDITORS Nancy McKee, M.D. Karol Wroblewski, M.Sc. (0T4) Martin C. Chang, Ph.D. (0T3) Maria Muraca, M.Sc. (0T3) Catherine Chung, B.Sc. (0T3) David Naylor, M.D., D.Phil. LAYOUT EDITOR Peter Ray, M.D., Ph.D. Andrea E. Waddell, B.Sc. (0T3) SENIOR TECHNOLOGY REVIEW EDITOR Andrew Schumacher, Ph.D. (0T1) Victor X.D. Yang, M.A.Sc. (MD/PhD3) Nicholas Tan, B.Sc. (0T3) MANAGING EDITORS David B.Yan, M.D. Mohammed Ali Warsi, M.Sc. (0T3) BOOK REVIEW EDITOR Sharon Cushing, B.Sc. (0T3) Irfan A. Dhalla, B.A.Sc. (0T3) Anand Govindarajan, B.Sc. (0T3) FACULTY ADVISORY BOARD Natalie Kontakos, B.Sc. (0T3) SENIOR COPY EDITORS Chair, Allan S. Detsky, M.D., Ph.D. Paul J. Belletrutti, B.Sc. (0T3) Jane Aubin JUNIOR MANAGING EDITOR Philip M. Buckler B.Sc. (0T3) Michael Baker Larry Pan, B.Sc. (0T4) Dawn Owen, B.Sc. (MD/PhD 2) John Chalis Jay S. Keystone TREASURER JUNIOR COPY EDITORS Murray Krahn Christopher A.K.Y. Chong, B.Sc. (0T3) Timothy Hanna B.Sc. (0T4) Tony Lang Amy E. Lin, B.Sc. (0T4) David Naylor ART DIRECTORS Anil J. Misir B.Sc. (0T4) Andree Jenks, B.Sc. (M.Sc. BMC, 0T1) Christina R. Tunzi, M.Sc. (0T4) Don Redelmeier Victoria Rowsell, B.Sc. (M.Sc. BMC, 0T1) June Ma, B.Sc. (0T4) Duncan Stewart Sharon E. Straus SENIOR NEWS AND VIEWS EDITORS WEBMASTER Donald Stuss Philippe L. Bedard, B.ArtsSc. (0T3) Errol Colak, B.Sc. (0T3) Ian Tannock Steve K. Singh, B.Sc. (0T3) Bryce Taylor JUNIOR WEBMASTERS John Trachtenberg NEWS AND VIEWS SERIES EDITORS Ralph Baddour, B.Sc., B.E.Sc. (0T4) Donald Wasylenki Back-to-Basics Olivia Y.Y Cheng, B.Sc. (0T4) Murray J. Beuerlein, M.Sc. (0T3) Christopher J. Hall, (0T3) HISTORICAL REVIEW EDITORS TYPESETTING Law and Ethics in Medicine Jewel Samadder, B.Sc. (0T3) Type and Graphics Manish Shah, B.Sc. (0T3) Vladislav Miropolsky, B.Sc. (0T3) Prolific Scientist Profile Rohit Bose, B.Sc. (MD/PhD2) JUNIOR HISTORICAL REVIEW EDITORS Julia Grebenyuk, B.Sc. (0T4) JUNIOR NEWS AND VIEWS EDITORS Karoon C. Danayan, B.Sc. (0T4) Ann M. Stewart, M.Sc. (0T4) E-mail: [email protected] • http://www.utmj.org • Phone: (416) 946-3047 • Fax: (416) 971-2163 2 University of Toronto Medical Journal UTMJ Subscribers The University of Toronto Medical Journal is funded in part by its subscribers and the Medical Society.
Load more

Recommended publications
  • Department of Medicine Annual Report 2018-2020 Cover: Dr
    Department of Medicine Annual Report 2018-2020 Cover: Dr. Verdu and her Research Team Top row: Dr. Heather Galipeau, Dr. Elena Verdu Middle row: Dr. Xuanyu Wang, Dr. Alba Santiago Bottom row: Dr. Marco Constante, Dr. Josie Libertucci A United Team with a common purpose: Dr. Verdu’s Research Team investigates diet-microbiota In addition to being committed to research excellence, this team interactions in chronic intestinal disorders. The team’s line of is committed to each other and to the wellbeing of others. The research includes: the metabolic activity of gut bacteria on the members of this high performing team have been consistent digestion of the dietary protein and gluten, the role of proteolytic supporters of charity events to raise awareness and funds for imbalance in ulcerative colitis, and the contribution of proteolytic the “Canadian Digestive Health Foundation” and “Crohn’s and bacteria to colonic inflammation. The team also explores Colitis of Canada” research, recently surpassing their target mechanisms through which microbes can modulate intestinal fundraising goal at the last virtual GUTSY Walk 2021event. As a inflammation and mechanisms that could help develop therapies to collective team, they have weathered the COVID-19 pandemic and treat celiac disease, and ulcerative colitis. have come together on this cover to illustrate that their common purpose and “united team” approach has not wavered even in this virtually connected world. Our Goals To facilitate the provision of the highest possible quality of care of the medical diseases of adults, giving appropriate consideration to costs and utilities. To take responsibility for the quality of the education programs offered by McMaster University for physicians in training and practice in the disciplines of general internal medicine and the medical subspecialities and to provide many of the planners and teachers for this broad undertaking.
    [Show full text]
  • Molecular and Cellular Biology Volume 4 - December 1984 C Number 12
    MOLECULAR AND CELLULAR BIOLOGY VOLUME 4 - DECEMBER 1984 C NUMBER 12 Aaron J. Shatkin, Editor in Chief(1985) Louis Siminovitch, Editor (1985) Roche Institute of Molecular Biology Hospital for Sick Children Nutley, N.J. Toronto, Canada Harvey F. Lodish, Editor (1986) Paul S. Sypherd, Editor (1985) Whitehead Institute for Biomedical University of California Research Irvine, Calif. Cambridge, Mass. Harold E. Varmus, Editor (1989) David J. L. Luck, Editor (1987) University of California Rockefeller University San Francisco New York, N.Y. EDITORIAL BOARD Renato Baserga (1985) Ari Helenius (1984) Steven McKnight (1986) Milton J. Schlesinger (1986) Alan Bernstein (1984) Susan A. Henry (1985) Robert L. Metzenberg (1985) Phillip A. Sharp (1985) J. Michael Bishop (1984) Ira Herskowitz (1984) Robert K. Mortimer (1985) Fred Sherman (1985) Joan Brugge (1985) James B. Hicks (1986) Paul Neiman (1986) Anna Marie Skalka (1986) Breck Byers (1985) John A. Carbon (1984) Tony Hunter (1986) Harvey L. Ozer (1985) Pamela Stanley (1985) Lawrence A. Chasin (1985) Larry Kedes (1985) Mary Lou Pardue (1985) Joan A. Steitz (1985) Nam-Hai Chua (1985) Barbara Knowles (1986) Mark Pearson (1985) James L. Van Etten (1985) Terrance G. Cooper (1984) Marilyn Kozak (1985) Jeremy Pickett-Heaps (1985) Jonathan R. Warner (1984) James E. Darnell, Jr. (1985) Monty Krieger (1986) Robert E. Pollack (1985) Robert A. Weinberg (1984) Gary Felsenfeld (1985) Elias Lazarides (1985) Keith R. Porter (1985) I. Bernard Weinstein (1985) Norton B. Gilula (1985) John B. Little (1985) John R. Pringle (1985) Harold Weintraub (1985) James E. Haber (1984) William F. Loomis, Jr. (1985) Daniel B. Rifkin (1985) Reed B.
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • Michel Foucault Ronald C Kessler Graham Colditz Sigmund Freud
    ANK RESEARCHER ORGANIZATION H INDEX CITATIONS 1 Michel Foucault Collège de France 296 1026230 2 Ronald C Kessler Harvard University 289 392494 3 Graham Colditz Washington University in St Louis 288 316548 4 Sigmund Freud University of Vienna 284 552109 Brigham and Women's Hospital 5 284 332728 JoAnn E Manson Harvard Medical School 6 Shizuo Akira Osaka University 276 362588 Centre de Sociologie Européenne; 7 274 771039 Pierre Bourdieu Collège de France Massachusetts Institute of Technology 8 273 308874 Robert Langer MIT 9 Eric Lander Broad Institute Harvard MIT 272 454569 10 Bert Vogelstein Johns Hopkins University 270 410260 Brigham and Women's Hospital 11 267 363862 Eugene Braunwald Harvard Medical School Ecole Polytechnique Fédérale de 12 264 364838 Michael Graetzel Lausanne 13 Frank B Hu Harvard University 256 307111 14 Yi Hwa Liu Yale University 255 332019 15 M A Caligiuri City of Hope National Medical Center 253 345173 16 Gordon Guyatt McMaster University 252 284725 17 Salim Yusuf McMaster University 250 357419 18 Michael Karin University of California San Diego 250 273000 Yale University; Howard Hughes 19 244 221895 Richard A Flavell Medical Institute 20 T W Robbins University of Cambridge 239 180615 21 Zhong Lin Wang Georgia Institute of Technology 238 234085 22 Martín Heidegger Universität Freiburg 234 335652 23 Paul M Ridker Harvard Medical School 234 318801 24 Daniel Levy National Institutes of Health NIH 232 286694 25 Guido Kroemer INSERM 231 240372 26 Steven A Rosenberg National Institutes of Health NIH 231 224154 Max Planck
    [Show full text]
  • Hematology-Oncology Fellow, H
    ® ASH NEWS AND REPORTS JULY/AUGUST 2017 VOLUME 14 ISSUE 4 DIFFUSION FEATURE More Than an Aspirin a Day to Keep Disparities of Adolescent and Young Adult Patients in Recurrent Venous Thromboembolism Away the Treatment of Malignant Hematologic Diseases Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for LEIDY L. ISENALUMHE, MD, MS extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211-1222. Adult Clinical Hematology-Oncology Fellow, H. Lee Moffitt Cancer Center and Research Institute; Pediatric Hematologist/ Oncologist; Chair, ASH Trainee Council; Tampa, FL hether to extend anticoagulant therapy for a deep The Adolescent and Young Adult (AYA) Progress Review Group (PRG) defines the vein thrombosis or pulmonary embolism beyond the AYA cancer population as patients ranging from 15 to 39 years of age. An estimated acute treatment period can be a problematic decision. 69,000 AYA individuals are diagnosed with cancer each year — six times more than Anticoagulant therapy reduces the risk of recurrent venous children younger than 14 years.1 The AYA age demarcation was established as a Wthromboembolic events (VTE), but at the cost of an increased risk of high-risk population after data from the Surveillance, Epidemiology, and End Results 1-3 bleeding. Reducing the intensity of anticoagulant therapy or switching (SEER) study showed a lack in improvement in survival for patients with many forms 3 to aspirin have both been proposed as options in patients who wish of cancer.2,3 The most common malignancies are leukemia, lymphoma, germ cell tumors, and central to continue protection, but the efficacy and safety of these strategies is nervous system tumors among 15 to 24 year olds, with the incidence of breast cancer, colorectal still uncertain.
    [Show full text]
  • David L Sackett: Interview in 2014 and 2015
    David L Sackett: Interview in 2014 and 2015 Page 1 of 103 David L. Sackett: Interview in 2014-2015 Copyright © 2015 by David L. Sackett No part of this manuscript may be reproduced in any form or by electronic means, including information storage and retrieval systems, without permission in writing from the editor, R Brian Haynes ([email protected]), except by a reviewer who may quote brief passages in review. Page 2 of 103 David L. Sackett: Interview in 2014-2015 Contents Preface and Editor’s Preface….5 Career Thumbnail….7 Section I: The Making of a Clinical Epidemiologist: 1934 – 1967….8 Chapter I-1: Where did you grow up, and what were you like as a kid?....8 Chapter I-2: Tell us about your college education, what you learned there that you used later, and how it led you to choose a medical career. ….10 Chapter I-3: Tell us about medical school. What happened there, and how did it shape your later career?....12 Chapter I-4: Tell us about your internship, (1st) residency, and sub-specialty training. What happened there, and how did it shape your later career?....17 Chapter I-5: Tell us about your time in the U. S. Public Health Service. What happened there, and how did it shape your later career?....20 Chapter I-6: Tell us about that 3rd year of post-graduate clinical training in Buffalo. What happened there, and how did it shape your later career?....24 Chapter I-7: Tell us about your time in Boston. What happened there and how did it shape your later career?....26 Section II: McMaster Medical School: 1967 – 1994….29 Chapter II-1:
    [Show full text]
  • In This Issue: Allergen Congratulates Dr
    Fall 2012 Welcome New AllerGen Board Chair In this issue: AllerGen congratulates Dr. pioneered the precursor to Howard Bergman on his Québec’s CLSCs (local New AllerGen Board Chair appointment as Chair of the community service centres) and Outgoing AllerGen Board Chair AllerGen Board of Directors Family Medicine Groups – les (BOD) for a three-year term, Cliniques populaires – and has New AllerGen Board Members effective June 26, 2012 to remained a fervent champion in October 25, 2015. the areas of primary care, aging, Outgoing AllerGen Board chronic disease, frailty and Members Dr. Bergman has been a health services throughout his New Committee Members member of the AllerGen career. He co-founded and co- Board of Directors since directed Solidage, a McGill Introducing 2012-2016 February 15, 2010. He is University-Université de Research Leaders currently the Chair of the Montréal Research Group on Past Research Leaders Department of Family Frailty and Aging. He was also co-founder and co-director Medicine, Professor of of the Jewish General Hospital-McGill University Memory Introducing New Staff Member Medicine, Family Medicine Clinic and Research Program. He is internationally and Oncology and the first Dr. recognized for his research on integrated care, frailty and Lengthy Road to Renewal Joseph Kaufmann Professor chronic disease, with over 150 publications. of Geriatric Medicine at McGill CIHR’s IHDCYH Strategic University and the Jewish Dr. Bergman is a Fellow of the Canadian Academy of Planning General Hospital. He is also Health Sciences. He is a Past President of the Canadian 2012 AllerGen Trainee an Adjunct Professor in the Geriatrics Society, which awarded him the Ronald Cape Department of Health Distinguished Service Award.
    [Show full text]
  • More Than Microscopes: the DIFFERENCE CANADIANS MAKE SAVING LIVES THROUGH MEDICAL RESEARCH
    More Than Microscopes: THE DIFFERENCE CANADIANS MAKE SAVING LIVES THROUGH MEDICAL RESEARCH healthpartners.ca 150 YEARS … 150 MEDICAL RESEARCH ADVANCES … $150 MILLION RAISED: Canadian Researchers Make a Mark Here — and Around the World Rick Perciante, Chair, Eileen Dooley Board of Directors CEO, HealthPartners HealthPartners Pablum to improve infant nutrition. The ability of Without a breakthrough using stem cell-based T-cells to destroy bacteria and viruses and marshal therapy to treat aggressive forms of relapsing- the immune system. The Cobalt-60 ‘bomb’ to remitting multiple sclerosis, Jennifer Molson kill cancer cells. Controlled gene mutation. The wouldn’t have been able to participate in a link between stress and disease. Insulin to treat bone marrow transplant trial, which essentially diabetes. Child-resistant medical containers. transformed her life. Without ground-breaking Discovery of stem cells. drug therapies, eight-year-old Kaiden Ames would probably not be alive today, and his Despite an overall population of fewer than parents wouldn’t have the chance to see him 40 million, Canada has nurtured a striking number grow up and even be a parent himself. Without of scientists and researchers whose breakthrough deep brain stimulation surgery, Herb Durand medical discoveries — and their ongoing wouldn’t be able to fulfill a long-time dream: to contributions to medical knowledge — have hold his grandchild. And without the tremendous improved, or have the potential to improve, the strides that have been made in diabetes research, health of millions of people around the world, not Dwayne Vermette certainly wouldn’t be living a just across our vast country. healthy lifestyle after being diagnosed with type 2 diabetes in his 30s — including having the ability HealthPartners is proud to play a leadership role to manage his condition with pills rather than a in connecting donor dollars to life-enhancing and daily injection of insulin.
    [Show full text]
  • Hamilton Biotech Profile
    Hamilton Biotechnology Profile 2002 Elements that create an appealing environment World Class Science Unrivalled Tax Advantages Hamilton… A premier location for future biotechnology Superior developments Quality of Life Globally Connected Research and Development: Pickard & Laws Consulting Group (905) 824-2446 Designed and Produced by: E-DESIGN GROUP • (905) 567-3983 • WWW.EDG.CA Photography: Dennis R. McGreal 2 Hamilton… an emerging centre for biotechnology The 21st century will be the century of biotechnology. An aging population will see health “Microelectronics, computers, enhanced and quality of life increased through synergistic advances in science and technology. telecommunications, designer This profile highlights how the City of Hamilton is poised to make a significant contribution to the bioscience revolution by: materials, robotics and • Describing the significance of biotechnology and its growth in Canada biotechnology are • Detailing Hamilton’s advantages as an emerging centre of transforming all facets of life biotechnology excellence • Providing information about joining this vibrant emerging industrial – what we do and how we do cluster in Hamilton it. Biotechnology is changing Today a new industrial revolution is underway… the characteristics of life Although we tend to think of biotechnology as a new economic sector, its roots go back centuries itself. New plants and animals to the time when beer was first fermented. Indeed, early biotechnology was almost exclusively focused on fermentation techniques to produce drinks, food and fuel. Around the time of World with different characteristics War I, these techniques were used to manufacture solvents. are being built.” Second generation biotechnology emerged after World War II. It involved the integration of Lestor Thurow Building Wealth microbiology, biochemistry and chemical engineering for large scale fermentation, sewage HarperCollins Publisher treatment, and for applications in the chemical and pharmaceutical industries.
    [Show full text]
  • Front Matter
    MOLECULAR AND CELLULAR BIOLOGY VOLUME 3 * NUMBER 12 * DECEMBER 1983 Aaron J. Shatkin, Editor in Chief (1985) Roche Institute of Molecular Biology Nutley, N.J. Harvey F. Lodish, Editor (1986) Louis Siminovitch, Editor (1985) Massachusetts Institute of Technology Hospital for Sick Children Cambridge, Mass. Toronto, Canada David J. L. Luck, Editor (1987) Paul S. Sypherd, Editor (1985) Rockefeller University University of California New York, N.Y. Irvine, Calif. EDITORIAL BOARD Renato Baserga (1985) Ira Herskowitz (1984) Daniel B. Rifkin (1985) Alan Bernstein (1984) Larry Kedes (1985) Robert G. Roeder (1985) J. Michael Bishop (1984) Marilyn Kozak (1985) James E. Rothman (1984) Joan Brugge (1985) Elias Lazarides (1985) Phillip A. Sharp (1985) Breck Byers (1985) John B. Little (1985) Fred Sherman (1985) John A. Carbon (1984) William F. Loomis, Jr. (1985) Pamela Stanley (1985) Lawrence A. Chasin (1985) Paul T. Magee (1985) Joan A. Steitz (1985) Nam-Hai Chua (1985) Robert L. Metzenberg (1985) James L. Van Etten (1985) Terrance G. Cooper (1984) Robert K. Mortimer (1985) Jonathan R. Warner (1984) James E. Darneil, Jr. (1985) Harvey L. Ozer (1985) Robert A. Weinberg (1984) Gary Felsenfeld (1985) Mary Lou Pardue (1985) I. Bernard Weinstein (1985) Norton B. Gilula (1985) Mark Pearson (1985) Harold Weintraub (1985) James E. Haber (1984) Jeremy Pickett-Heaps (1985) Reed B. Wickner (1985) Benjamin Hall (1985) Robert E. Pollack (1985) Leslie Wilson (1985) Ari Helenius (1984) Keith R. Porter (1985) Edward Ziff (1985) Susan A. Henry (1985) John R. Pringle (1985) Helen R. Whiteley, Chairman, Publications Board Walter G. Peter Ill, Director, Publications Linda M. Illig, Managing Editor, Journals Eleanor S.
    [Show full text]
  • More Than Microscopes: the DIFFERENCE CANADIANS MAKE SAVING LIVES THROUGH MEDICAL RESEARCH
    More Than Microscopes: THE DIFFERENCE CANADIANS MAKE SAVING LIVES THROUGH MEDICAL RESEARCH healthpartners.ca 150 YEARS … 150 MEDICAL RESEARCH ADVANCES … $150 MILLION RAISED: Canadian Researchers Make a Mark Here — and Around the World Rick Perciante, Chair, Eileen Dooley Board of Directors CEO, HealthPartners HealthPartners Pablum to improve infant nutrition. The ability of Without a breakthrough using stem cell-based T-cells to destroy bacteria and viruses and marshal therapy to treat aggressive forms of relapsing- the immune system. The Cobalt-60 ‘bomb’ to remitting multiple sclerosis, Jennifer Molson kill cancer cells. Controlled gene mutation. The wouldn’t have been able to participate in a link between stress and disease. Insulin to treat bone marrow transplant trial, which essentially diabetes. Child-resistant medical containers. transformed her life. Without ground-breaking Discovery of stem cells. drug therapies, eight-year-old Kaiden Ames would probably not be alive today, and his Despite an overall population of fewer than parents wouldn’t have the chance to see him 40 million, Canada has nurtured a striking number grow up and even be a parent himself. Without of scientists and researchers whose breakthrough deep brain stimulation surgery, Herb Durand medical discoveries — and their ongoing wouldn’t be able to fulfill a long-time dream: to contributions to medical knowledge — have hold his grandchild. And without the tremendous improved, or have the potential to improve, the strides that have been made in diabetes research, health of millions of people around the world, not Dwayne Vermette certainly wouldn’t be living a just across our vast country. healthy lifestyle after being diagnosed with type 2 diabetes in his 30s — including having the ability HealthPartners is proud to play a leadership role to manage his condition with pills rather than a in connecting donor dollars to life-enhancing and daily injection of insulin.
    [Show full text]
  • Evidensbaserat Socialt Arbete: Från Idé Till Praktik
    Evidensbaserat socialt arbete: Från idé till praktik Kajsa Svanevie Umeå universitet/Umeå University Institutionen för socialt arbete/Department of Social Work Umeå 2011 This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7459-319-8 ISSN: 0283-300-67 Omslag: Pär Andersson Omslagsbild: Kajsa Svanevie Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print & Media Umeå, Sverige 2011 Historien erbjuder såvitt jag vet aldrig någon väg tillbaka. Det finns inga pendelrörelser som innebär att utvecklingen rör sig fram och åter. Utvecklingen rör sig alltid framåt, även om detta naturligtvis inte alltid, eller långt ifrån alltid, innebär framsteg. (Bengt Börjeson) i Svanevie, Kajsa, 2011: Evidensbaserat socialt arbete: Från idé till praktik. (Evidence-based social work: From idea to practice). Monograph. Language: Swedish, with a summary in Eng- lish. Umeå University, Department of Social Work, SE-901 87 Umeå, Sweden. Doctoral Dissertation at the Faculty of Social Sciences. ISBN: 978-91-7459-319-8 ISSN: 0283-300-67 Abstract As an innovation Evidence-Based Practice (EBP) is designed as a tool for clinical problem solving. According to its theory of use EBP will bring a difference for policy makers, for professionals, for researchers and for service users. One question to be asked is whether EBP actually leads to the radical social change it is designed to accomplish. The aim of the study is to describe and analyse the outcome of the effort to establish EBP, with a focus on the case of social work in Sweden. The research questions are: What is EBP? Why are efforts made to establish EBP? What is the outcome of the EBP project? How can the outcome of the EBP project be explained? The case study was conducted on a critical realistic meta-theoretical ground with a focus on explanation of social change with an explicit actor-structure perspective.
    [Show full text]